We describe a case of prolonged cholestasis temporally associated with the
use of itraconazole for onychomycosis. Peak bilirubin level of 32.0 mg/dl w
as documented approximately 2 months after discontinuation of the patient's
itraconazole therapy, with symptoms of cholestasis persisting more than 1
month after the peak in bilirubin. Physicians should be aware of the potent
ial for severe cholestasis associated with itraconazole usage. (Am J Gastro
enterol 1999;94:3632-3633. (C) 1999 by Am. Coll. of Gastroenterology).